While it is now fully recognised that grey matter (GM) lesions are at least as abundant as white matter lesions in multiple sclerosis (MS), it is hard to imagine that it was only a decade ago that the first deliberate attempt was made to visualise GM lesions with magnetic resonance imaging (MRI). An initial study showed that using conventional T2-weighted and threedimensional (3D) fluid-attenuated inversion recovery (FLAIR) imaging, only ~5% of GM lesions were detected, 1 and this disappointing finding spurred the development of MRI techniques that would improve on this. Soon after, double inversion recovery (DIR) -which suppresses signals from both cerebrospinal fluid and white matter, making GM more conspicuous -was applied to solve this sensitivity problem and proved superior to both FLAIR and T2 in detecting cortical GM lesions. 2 However, DIR images often exhibit artefacts that can be mistaken for GM lesions, for example, small vascular structures or incompletely suppressed fluid in Virchow-Robin spaces posed a problem. A magnetic resonance imaging in multiple sclerosis (MAGNIMS) study group produced consensus criteria to facilitate reliable identification of GM lesions on DIR images, 3 and using these criteria in a post-mortem study, pathological specificity was shown to be high (90%) but sensitivity lingered around a disappointing 20%. 4 So further techniques -aiming to either complement or replace DIR -were tried. 3D-T1-based techniques, 5 T2*-weighted imaging, 6 phase-sensitive inversion recovery (PSIR) 7 and creative combinations of all of the above were investigated. Whether or not any of these techniques should be considered 'better than the other' remains open to debate, given the often imperfect conditions of comparison, but, importantly, all of them still show only the tip of the proverbial iceberg. 8 Following this, researchers turned to higher fieldstrengths to further improve cortical lesion detection in MS. With better spatial resolution, sensitivity for cortical demyelination increased from 20% when using DIR at standard clinical field-strengths 4 to 30%-50% with T2(*)-weighted imaging at 7 T. 9-11 But this still means that at least half of the total number of cortical lesions are missed. Reflexively, we feel that we should improve this state of affairs, invest more research time and funds into further development of MRI techniques, higher fields or both. But it might be good to pause for a moment and ask ourselves to what end would we act upon this reflex. For one, conventional imaging (e.g. T2-weighted and FLAIR scans), used to detect white matter lesions, has served us well in diagnostic criteria and in treatment trials, yet still only detects between 60% and 70% of such lesions. 1 In general, a number of clinical reasons for further improving cortical lesion visualisation with MRI could be thought of: greater diagnostic accuracy, more robust prognostication or better monitoring of therapeutic effects. So far, studying cortical lesions at clinical (1.5 T and 3 T) field-strengths has indeed resulted in a solid body of evidence showing an association between cortical lesions and disability, including cognitive impairment. 12 Taking cortical lesions into account appears to increase the diagnostic accuracy of MRI criteria 13 and has prognostic value. 14 The presence of cortical pathology also helps distinguish between MS and its mimics. 15 However, the question is whether or not visualising more cortical lesions in MS patients will really make any further difference? We already know that the tip is representative of the whole iceberg, 4 unless, of course, the type of lesions that we currently see on MRI is different from the type of lesions that remain obscure. And, granted, that seems to be the case. Even at ultra-high field-strength (7 T), despite being the most abundant type, subpial GM lesions are rarely seen. 9 This could be seen as a problem for those of us arguing that there is no compelling reason to further improve GM lesion visualisation. However, there is no convincing evidence that subpial lesions are pathologically distinct or more (or differentially) clinically eloquent than the other types of cortical lesion that we do see more readily on MRI.
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Correlations between cortical lesions and clinical deficits are certainly present but they are modest.
Realising this need not drive us to improve our measurement simply to be able to confirm correlations in smaller cohorts. Instead, in a complex, multifactorial disease like MS, in which multiple different pathologies may be clinically relevant, perhaps we should aim to explain clinical variance better by integrating measures of these different pathologies rather than focusing on just one.
Of
With this in mind, rather than trying to improve visualisation of GM lesions by feverishly developing new MRI methods, a more cost-efficient option should probably be tried first. Recent work provided a clue as to what can be done to improve lesion detection while using already existing methodology. Jonkman et al. 10 compared 7 T T2*-weighted MRI with histopathology findings and showed that although prospective scoring (i.e. without knowing where a lesion was before scoring) identified only about 30% of lesions, retrospectively (i.e. after the location of the lesion had been revealed) ~85% of lesions were visible. This serves to show that there is substantial potential for gains in lesion detection even using the scans already available to us, through better training of operators. Now may be a good time to organise an international meeting to refine the MAGNIMS consensus criteria for GM lesion marking, originally based on DIR, for use with other more recently introduced imaging methods.
In conclusion, although we recognise the potential for further improvement of cortical lesion visualisation, we should keep in mind the reasons for doing so and not simply pursue this because of the general belief that 'more must be better'.
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Visualization of cortical MS lesions with MRI need not be further improved -No Caterina Mainero and Tobias Granberg
Cortical lesions are an established pathological feature of multiple sclerosis (MS) and one of the main substrates of MS disease progression. 1 Despite recent advances in imaging using ultra-high-field strength magnetic resonance imaging (MRI), histopathological-MRI correlative examinations show that a variable proportion of cortical lesions go undetected at visual examinations of MRI scans. 2, 3 This affects predominantly subpial lesions, the most common cortical lesional histopathological type in MS, located in the juxtameningeal cortical layers. 1 Here, we argue that further improvement of visualization of cortical MS lesions with MRI, particularly the subpial type, is needed to better understand cortical MS lesion pathogenesis and its role in neurodegeneration and, in clinical practice, for increasing the sensitivity and specificity of MS diagnosis, as well as for monitoring disease progression and treatment response in patients with definite MS.
Knowledge of cortical lesion pathogenesis in MS is limited and mostly derives from post-mortem examinations of MS brains. Pathological studies report that the histopathological and immunological characteristics of cortical lesions seem to differ significantly from those observed in the white matter (WM), suggesting a location-dependent expression of the MS immunopathological process. 1 The inherent cross-sectional study design of pathological examinations, which does not lend itself to prospective repeated measures, prevents from temporal observations of suspected pathophysiologic pathways, which in turn could help to establish etiologic causation in cortical lesion development as well as differences from neuropathological processes occurring in WM. Additionally, post-mortem studies tend to skew tissue samples toward older individuals with established disease and with possible comorbidities that may confound the analysis, while under-representing early disease. Improvements in cortical lesion visualization in vivo would be extremely valuable for monitoring longitudinally cortical lesion dynamics from the earliest MS disease stages and for assessing their relationship with underlying WM pathology as well as their independent contribution to neurodegeneration and to the establishment of irreversible disability.
Improvements in cortical lesion visualization in vivo, especially the subpial histopathological type, could also increase the sensitivity and specificity of MS diagnosis and aid in differential diagnosis. A recent review of MS diagnostic criteria suggested incorporating cortical lesions assessment in the dissemination in space criteria for MS, as an extension to the current inclusion of juxtacortical lesions. 4 Cortical lesions can indeed be detected in about one-third of patients with clinically isolated syndrome and are able to independently
